Candel Therapeutics

Did you know that only about 15-40% of patients with advanced non-small cell lung cancer (NSCLC) respond to standard immune checkpoint inhibitor (ICI) therapy? In honor of #HealthyLungMonth, let's raise awareness about the ongoing need for innovative treatments in lung cancer. At Candel, we are conducting a clinical trial of an investigational viral immunotherapy, CAN-2409, which could potentially convert non-responders to ICI into responders. This approach has shown promising results in patients with progressive disease despite ICI therapy. Learn more about our clinical trials: https://lnkd.in/dTeQgMFm #LungCancerResearch #ClinicalTrials #CancerAwareness #NSCLC 

President and CEO, Paul Peter Tak, MD PhD FMedSci, will join a panel with Sushil Patel, CEO of Replimune, at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024.    The discussion will cover product differentiation, data across indications, development steps, and manufacturing capabilities.    #Healthcare #Innovation #Leadership  

Our team is presenting a poster on CAN-3110’s activity in a model of #melanoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting!     See the details here: https://lnkd.in/eH3qq89Q    #SITC24  

We're committed to improving outcomes for #prostatecancer patients.  President and CEO, Paul Peter Tak, MD PhD FMedSci, discusses the need for better early-stage disease treatments and shares his thoughts on patient-centered innovation and the future of prostate cancer care in MedCity News: https://lnkd.in/gaVw4H-k    #CancerResearch #PatientFirst  

On #WorldCancerResearchDay, we recognize the relentless pursuit of innovative solutions to combat cancer. At Candel, we're developing second generation viral immunotherapies to empower an individual’s immune system to stand against cancer. Together, we can push the boundaries of science and bring new hope to those affected by this disease. Join us in the fight against cancer. #CancerResearch #WCRD2024

President and CEO, Paul Peter Tak, MD PhD FMedSci, will chair a panel with other experts to discuss the improvements and new approaches to treating autoimmune and inflammatory diseases at the BioCentury Inc. Grand Grounds. Learn more about the event here: https://bit.ly/3AFx6QJ

Chief Scientific Officer, Francesca Barone, MD, PhD, will present a poster on the second immunotherapy candidate from our enLIGHTEN™ Discovery Platform at BioCentury Ground Rounds. The first-in-class TLS-inducing multimodal immunotherapy candidate is being developed as a potential new treatment for solid tumors. Learn more about the event here: https://bit.ly/3AFx6QJ

President and CEO, Paul Peter Tak, MD PhD FMedSci, will discuss the latest company updates from Candel in a presentation at the H.C. Wainwright Annual Global Investment Conference. Listen to the presentation available on-demand here: https://bit.ly/3OHUqm0

We are on track for topline data from our fully enrolled phase 3 (intermediate/high-risk; n=711) and phase 2b (low/intermediate risk, active surveillance population; n=187) randomized controlled clinical trials in early, localized prostate cancer in Q4 2024. #viral #immunotherapy #prostate #cancer #CAN-2409

It is estimated that there will be approximately 299,000 new cases of prostate cancer cases in the United States in 2024. This Prostate Cancer Awareness Month, we stand with those affected by this disease. At Candel, we're advancing our viral immunotherapy, CAN-2409, designed to empower the immune system to fight cancer, including prostate cancer, more effectively. #ProstateCancerAwareness #EndCancer